S A Gronskaia, Zh E Belaya, L Ya Rozhinskaya, G A Melnichenko, T A Dubovitskaya, E O Mamedova, S S Rodionova, Yu V Buklemishev, E A Pigarova, M V Degtyarev, D M Babaeva, V P Vladimirova, N V Tarbaeva, S S Serzhenko, A Yu Grigoriev, L K Dzeranova, V Yu Karpenko, A L Karasev, R N Fedotov, I N Uliyanova, N V Toroptsova, O M Lesnyak, N G Mokrysheva, I I Dedov
INTRODUCTION: Tumor-induced osteomalacia is an acquired rare disease manifested by hypophosphatemic osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23). FGF 23 is a non-classical hormone secreted by bone tissue (osteocytes) and regulates phosphorus metabolism.The aim of this work is to present clinical experience in the diagnosis, treatment and rehabilitation of patients with tumor-induced osteomalacia. MATERIALS AND METHODS: 40 patients with clinically-confirmed tumor-induced osteomalacia were included in the study, 34 of whom had the tumor localized, 27 underwent surgical treatment and 21 achieved stable remission...
November 10, 2023: Problemy E̊ndokrinologii